Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2261

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure ; volume:21 ; number:1 ; day:21 ; month:7 ; year:2021 ; pages:1-8 ; date:12.2021
BMC cardiovascular disorders ; 21, Heft 1 (21.7.2021), 1-8, 12.2021

Creator: Nakagaito, Masaki
Imamura, Teruhiko
Joho, Shuji
Ushijima, Ryuichi
Nakamura, Makiko
Kinugawa, Koichiro

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12872-021-02163-7

URN: urn:nbn:de:101:1-2021102302091038204889

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Nakagaito, Masaki
Imamura, Teruhiko
Joho, Shuji
Ushijima, Ryuichi
Nakamura, Makiko
Kinugawa, Koichiro
SpringerLink (Online service)

Other Objects (12)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

$Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction$

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Iatrogenic Decompensated Heart Failure

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

Related objects

Reset password